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1. INTRODUCTION: 
The word new or novel in the relation to drug delivery 
system is a search for something out of necessity. An 
appropriately designed sustained or controlled release drug 
delivery system can be major advance toward solving the 
problem associated with the existing drug delivery system 
1,2. Various attempts have been made to prolong the gastric 
residence time of dosage form in the stomach. Floating 
drug delivery system have a bulk density less than gastric 
fluids and so remains buoyant in the stomach without 
affecting gastric emptying rate for a prolonged period of 
time. While the system is floating on the gastric contents, 
the drug is released slowly at the desired rate from the 
system. After release of drug, the residual system is 
emptied from stomach.  
This result in an increased gastric residence time and a 
better control of the fluctuation in plasma drug 
concentration 3. Single unit formulations are associated 
with problems such as sticking together or being 
obstructed in the gastrointestinal tract, which may have a 
potential danger of producing irritation. On the other hand 
a floating system made of multiple unit forms has relative 
merits compared to a single unit preparation. Indeed the 
gastric emptying of a microparticulate floating system 
would occur in consistent manner with small individual 
variations on each subsequent gastric emptying sunken 
particles will spread out over a large area of absorption 
sites, increasing the opportunity of drug release and 
absorption in a more or less predictable way. Moreover, 
since each dose consists of many subunits, the risk of dose 
duping is reduced 4. Floating microspheres provide a 
constant and prolonged therapeutic effect which will 
reduce dosing frequency. 5, 6 Eletriptan Hydrobromide is an 
antimigraine drug; its mechanism of action is explained by 
two theories to explain the efficacy of 5-HT receptor 
agonists in migraine. One theory the suggests that 
activation of 5-HT1 receptors located on intracranial blood 
vessels, including those on the arterio venous anastomoses, 
leads to vasoconstriction, which is correlated with the 
relief of migraine headache. The other hypothesis suggests 
that activation of 5-HT1 receptors on sensory nerve 
endings in the trigeminal system results in the inhibition of 
proinflammatory neuropeptide release. Inhibition of 
prostaglandin synthetase and its plasma elimination half 
life is 4 hrs and in order to maintain therapeutic plasma 
level drug must be administered at least twice a day7. 
The aim of this study was to prepare Eletriptan 
Hydrobromide floating microspheres containing 
hydrophobic polymer ethyl cellulose along with low 
density calcium silicate porous carrier and ion exchange 
resin Cholestyramine to achieve better encapsulation 
efficiency, better buoyancy and sustained drug release 
profile suitable for oral administration. The influences of 
formulation variables on the microsphere properties were 
examined and the microsphere formulations suitable to 
achieve our goal were determined. 
2. MATERIALS AND METHOD: 
2.1. Materials: 
Eletriptan Hydrobromide was received as a gift sample 
from Finosa Pharmaceuticals, Hyderabad, India. Calcium 
silicate was procured from Johnson & George Chemical 
company, Mumbai, Ethyl cellulose was a gift sample from 
Merck, Mumbai, Acetonitrile, Dichloromethane and Light 
liquid paraffin and other chemicals were of analytical 
grade. 
2.2. Methods: 
2.2.1. Preparation of Eletriptan Hydrobromide 
adsorbed Calcium silicate:  
The porous carrier was dispersed into 10 ml water solution 
of drug (Eletriptan Hydrobromide). This solution was 
ultrasonicated to imbibe the drug solution inside the pores 
of porous carrier8.  
2.2.2. Preparation of Eletriptan Hydrobromide –
Cholestyramine complex: 
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An accurately weighed amount of Eletriptan 
Hydrobromide (100 mg) was taken and added in 10 ml of 
distilled water. Then known weight of ion exchange resin 
was added to the solution and stirred on propeller stirrer. 
Resinate thus formed was washed with 0.1 N HCl to 
remove the unloaded drug. Resinate was dried overnight in 
an hot air oven at 50ºC 9. 
2.2.3. Preparation of floating microspheres:  
Microspheres were prepared using a modified water-in oil-
in oil (W/O1/O2) double emulsion solvent diffusion 
method10. Briefly, for calcium silicate and cholestyramine 
based microspheres, the drug adsorbed calcium silicate and 
drug- cholestyramine complex was added respectively to 
the polymer solution of ethyl cellulose (EC) in acetonitrile 
and dichloromethane (CAN:DCM) (1:1) and stirred using 
a mechanical stirrer at 500 rpm.The resulting  W/O 
primary emulsion was slowly added to 50 ml of light 
liquid paraffin, the second oil phase containing 0.5% span 
80 as a surfactant while stirring by a paddle propeller at 
1000 rpm. After 2 h, 10 ml of n-hexane (non-solvent) was 
added to harden the microspheres and stirring was 
continued for a further 1 h and the hardened microspheres 
were collected by filtration and washed thrice  with 50 ml 
of  n-hexane and air dried for 12 h.The effect of process 
variables like polymer concentration, stirring rate, 
temperature, concentration of aqueous phase on the 
particle size, buoyancy, drug entrapment efficiency, drug 
release, amount of porous carrier and ion exchange resin 
were studied. 
 Process variables: Amount of Polymer: 1000, 1500 mg; 
Amount of carrier: 150, 200, and 250. 
3. Characterization of microspheres: 
3.1. Micromeritic properties: 
The microspheres were characterized by their micromeritic 
properties, such as particle size, true density, tapped 
density, compressibility index and flow properties. The 
size was measured using an optical microscope, and the 
mean particle size was calculated by measuring 200–300 
particles with the help of a calibrated ocular micrometer. 
The tapping method was used to determine the tapped 
density and percent compressibility index11 as follows: 
Tapped density = Mass of microspheres / Volume of 
microspheres after tapping 
% Compressibility index = (1- V/Vo)×100 
Here V and Vo are the volumes of the sample after and 
before the standard tapping, respectively.  
True density was determined using a benzene displacement 
method.  
Porosity  (ɛ) was calculated using the equation: 
ɛ = (1 _ Pp/Pt) ×100 
where Pt and Pp are the true density and tapped density, 
respectively. 
 Angle of repose h of the microspheres, which measures 
the resistance to particle flow, was determined by a fixed 
funnel method.
12
  and calculated as TanӨ=2h/D 
Where 2h/D is the surface area of the free standing height 
of the microspheres heap that is formed on a graph paper 
after making the microspheres flow from the glass funnel. 
3.2. Morphology: 
The external and internal morphology of the microparticles 
and porous carrier were studied by scanning electron 
microscopy (SEM). The samples for SEM were pre-pared 
by lightly sprinkling the powder on a double adhesive tape 
stuck to an aluminum stub. The stubs were then coated 
with gold to a thickness of about 300 A° under an argon 
atmosphere using a gold sputter module in a high-vacuum 
evaporator. The coated samples were then randomly 
scanned and photomicrographs were taken with a scanning 
electron microscope (Jeol JSM-1600, Tokyo, Japan). 
3.3. Determination of drug content of microspheres: 
Drug amount in microspheres was determined by 
dissolving 10 mg of each sample in 100 ml 
dichloromethane. The drug concentration was determined 
spectrophotometrically (UV-160, Shimadzu, Japan) at 
272.2 nm. All experiments were done in triplicate 9. 
3.4. Determination of production yield: 
The production yield of the microparticles was determined 
by calculating accurately the initial weight of the raw 
materials and the last weight of the microspheres 
obtained13. All of the experiments were performed in 
triplicate 
% drug entrapment = [calculated drug 
concentration/theoretical drug concentration] ×100. 
% yield = [total weight of floating microparticles /total 
weight of drug, polymer, porous carrier/resin (if added) 
×100. 
3.5. In -vivo floating behavior: 
Microspheres (50mg) were spread over the surface of a 
USP XXIV dissolution apparatus type II filled with 900 ml 
of 0.1 N Hydrochloric acid. The medium was agitated with 
a paddle rotating at 100 rpm for 12 h. The floating and the 
settled portions of microspheres were recovered separately. 
The microspheres were dried and weighed. Buoyancy 
percentage was calculated as the ratio of the mass of the 
microspheres that remained floating and the total mass of 
the microspheres14. 
Buoyancy= Wf /(Wf +Ws)×100 
Where Wf and Ws are the weights of the floating and 
settled microparticles, respectively. All the determinations 
were made in triplicate. 
3.6. In- vitro release studies: 
The drug release rate from floating microspheres was 
determined using USP XXIII basket type dissolution 
apparatus. A weighed amount of floating microspheres 
equivalent to 20 mg drug was filled into a capsule and 
placed in the basket. 0.1 N HCl was used as the dissolution 
medium and maintained at 37±0.5° C. at a rotation speed 
of 100 rpm. Perfect sink conditions prevailed during the 
drug release studies. Five ml sample was withdrawn at 
each 30 min interval, passed through a membrane filter 
(Millipore), and analyzed spectrophotometrically at 272.2 
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nm to determine the concentration of drug present in the 
dissolution medium. The initial volume of the dissolution 
fluid was maintained by adding 5 ml of fresh dissolution 
fluid after each withdrawal. All experiments were 
conducted in triplicate. 
3.7.    In- vivo floating behaviour: 
Barium sulphate loaded microspheres were prepared by 
adopting the procedure as described before except for 
using barium sulphate instead of drug. Healthy rabbit 
weighing approximately 2.3 Kg was used to assess in vivo 
floating behaviour. Ethical clearance for the handling of 
experimental animals was obtained from the 
SLS/2012/10/5/2(1047/ac/07/CPCSEA), constituted for 
the purpose. The animal was fasted for 12 h and the first 
X-ray photographed to ensure absence of radio opaque 
material in the stomach. The rabbit were made to swallow 
barium sulphate loaded microspheres with 30 ml of water. 
During the experiment rabbit were not allowed to eat but 
water was provided. At predetermined time intervals the 
radiograph of abdomen was taken using an X-ray 
machine15. 
3.8. Accelerated stability studies: 
Drug decomposition or degradation occurs during storage, 
because of chemical alteration of the active ingredients or 
due to product instability, leading to lower concentration 
of the drug in the dosage form, hence the stability of 
pharmaceutical preparation need to be evaluated. The 
objective of stability studies is to predict the shelf life of a 
product by accelerating the rate of decomposition, 
preferably by increasing the temperature and relative 
humidity (RH) conditions. Stability studies were carried 
out at 40±2 °C and 75± 5% relative humidity for 90 days16. 
4. RESULTS AND DISCUSSIONS: 
4.1. Formation of microspheres: 
Microspheres were formed after a series of steps like 
solvent extraction and solvent evaporation and addition of 
non-solvent. Acetonitrile is a unique organic solvent which 
is polar, water miscible and oil immiscible. All other polar 
solvents are oil-miscible and do not form emulsions of the 
polymer solution in oil17. Dichloromethane is non-polar 
and oil miscible. Using acetonitrile alone as a solvent did 
not ensure formation of a stable emulsion, and non-polar 
solvent such as dichloromethane was included to decrease 
polarity of the acetonitrile solution 18. Therefore, during 
the formation of microspheres, dichloromethane is 
extracted by liquid paraffin and acetonitrile is evaporated 
during stirring.The incorporation of drug adsorbed calcium 
silicate or drug – cholestyramine complex into the 
formulation may produce porous structure within the 
microspheres. The compositions are showed in Table.1.
 
Table 1: Composition of floating microspheres of Eletriptan hydrobromide 
EC: Ethylcellulose, (ACN: DCM): Acetonitrile: Dichloromethane 
 
4.2. Micromeritic properties: 
The mean particle sizes of calcium silicate powder was 
142 ± 02µm, while that of microsphere formulations 
containing calcium silicate in the range of 150 to 250mg 
measured 650 ± 12µm to 828 ± 12µm when compared to 
cholestyramine measured 605±15µm to 813±14µm. the 
particle size of microsphere formulation without buoyant 
material was found to be 180±08µm. The tapped density 
values of calcium silicate ranged from 0.33±0.04g/cm3 to 
0.65±0.06g/ cm3 that of tapped density values of 
cholestyramine ranged from 0.43±0.09g/ cm3 to 
0.68±0.07g/ cm3, while true density of calcium silicate 
ranged between 1.66±0.12g/ cm
3
 and 1.84±0.1g/ cm
3
 and 
cholestyramine ranged between 1.89±0.15g/ cm3 and 
2.11±0.5g/ cm3. The significant difference in the densities 
may be caused by the presence of low density calcium 
silicate and cholestyramine particles in the microspheres. 
The porosity of all the microsphere formulations was 
found to be in the range of 70.6%±2.5% to 90.0%±4.0%. 
The compressibility index of calcium silicate based 
formulations ranged between 14.73%±2.2% and 
24.6%±3.1% while that of calcium silicate based 
formulations ranged between 15.12%±4.2% and 
28.71%±4.3%. All formulations of calcium silicate showed 
excellent flow ability as expressed in terms of angle of 
repose (<40°) except formulation CS2C, probably due to 
higher content of calcium silicate, while in cholestyramine 
based formulations expressed flow ability in terms of angle 
of repose (<46°) except formulation CH2C, probably due 
Formulation Drug (mg) EC (mg) Calcium silicate (mg) 
Cholestyra-mine 
(mg) 
ACN:DCM(1:1)(ml) 
CS1A 100 1000 150 - 20 
CS1B 100 1000 200 - 20 
CS1C 100 1000 250 - 20 
CS2A 100 1500 150 - 20 
CS2B 100 1500 200 - 20 
CS2C 100 1500 250 - 20 
CH1A 100 1000 - 150 20 
CH1B 100 1000 - 200 20 
CH1C 100 1000 - 250 20 
CH2A 100 1500 - 150 20 
CH2B 100 1500 - 200 20 
CH2C 100 1500 - 250 20 
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to higher content of cholestyramine.  The better flow 
property indicates that the floating microspheres produced 
are non-aggregated. 
4.3. Morphology: 
Calcium silicate and cholestyramine based Ethyl cellulose 
microspheres were predominantly spherical in appearance; 
however some were found to be elongated. The porous 
nature and spherical shape of the microspheres are evident 
from their SEM photomicrographs Fig. 1, Fig. 2. As can be 
seen in the photomicrograph, there are many pores and 
cavities in the microspheres. Low-density drug adsorbed 
FLR particle is clearly visible inside the microsphere in 
Fig. 3 and Fig. 4, which make them float on the simulated 
GIT fluids shows the surface morphology of microsphere 
at a higher magnification. 
 
Fig. 1: SEM photomicrographs showing porous nature and 
spherical shape of calcium silicate based microspheres. 
 
 
Fig. 2: SEM photomicrograph depicting many pores and 
cavities in the cholestyramine based microspheres. 
 
Fig. 3:  SEM photomicrograph showing low-density drug 
adsorbed calcium silicate particle is clearly visible inside 
the microsphere. 
 
 
Fig. 4: SEM photomicrographs showing porous nature and 
spherical shape of cholestyramine based microspheres. 
Percentage buoyancy and drug entrapment: 
In Vitro Buoyancy percentage of the microspheres calcium 
silicate based Eletriptan hydrobromide was in the range of 
76.15 ± 0.55 % to 93.80 ± 1.75% at the end of 12 h above 
88 %) and that of cholestyramine based Eletriptan 
Hydrobromide 77.54 ± 1.73 to 91.83 ± 1.74 % at the end 
of 12 h as shown in Table. 2. Good in vitro floating 
behavior was observed for all the microsphere formulation. 
This may be attributed to the low density calcium silicate 
within the system. 
The percent drug  entrapment of calcium silicate based 
Eletriptan hydrobromide in all the formulations was in the 
range of 53.02  ± 4.97% to 75.29 ± 1.93% found to be 
good  at all levels of drug loading and that of 
cholestyramine based microspheres was in the range of 
19.96 ± 1.73% to 56.91 ± 4.49% as in Table.3. The extent 
of loading influenced the particle size distribution of 
microspheres. When the loading was high, the proportion 
of larger particles formed was also high. With 75% 
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entrapment, most of the particles(calcium silicate based) 
were in the size range of 84-100 micrometer, suitable for 
oral administration and with 57% entrapment, most of the 
particles(cholestyramine based) were in the size range of  
58.5-68.9micrometer, As the concentration of total amount 
of polymer was increased, drug entrapment efficiency 
(drug content) was also increased. Formulation CS2B 
showed good % drug entrapment (73.10 ± 1.93 %). 
Table 2: In-vitro buoyancy studies of Calcium silicate 
and Cholestyramine based Eletriptan Hydrobromide 
floating microspheres. 
Formulation  Total floating 
time(hr) 
% of Buoyancy  
CS1A >24 76.15  ± 0.55 
CS1B >24 86.81  ± 0.96 
CS1C >24 89.43  ± 4.43 
CS2A >24 86.21  ± 1.12 
CS2B >24 93.80  ± 1.75 
CS2C >24 90.96  ± 1.21 
CH1A >24 77.54  ± 1.73 
CH1B >24 80.49  ± 1.57 
CH1C >24 86.12  ± 0.97 
CH2A >24 82.77  ± 0.48 
CH2B >24 85.82  ± 1.20 
CH2C >24 91.83  ± 1.74 
 
Table 3:  Drug entrapment of floating microspheres 
Formulation code % Drug entrapment 
CS1A 53.02 ± 4.97 
CS1B 40.10 ± 9.62 
CS1C 61.87 ± 0.57 
CS2A 68.08 ± 0.98 
CS2B 75.29 ± 1.93 
CS2C 70.98 ± 0.59 
CH1A 19.96 ± 1.73 
CH1B 21.27± 0.63 
CH1C 24.08 ± 0.45 
CH2A 42.40 ± 1.77 
CH2B 46.99 ±  0.79 
CH2C 56.91 ± 4.49 
 
4.4. Production yield: 
The percentage yield of floating microspheres of 
formulations (CS1A to CS2C) was found to be in the range 
of 94.64 to 98.37% and 96.936 to 98.86% in 
cholestyramine based formulations (CH1A to CH2C) 
4.5. In- vivo floating behavior: 
 The in vivo floating behavior of formulation (CS2B and 
CH2C) hollow microspheres loaded with barium sulphate 
was investigated by radiographic images (X-ray 
photographs) of rabbit’s stomach at specific periods. The 
amount of X-ray opaque material in these hollow was 
sufficient to ensure visibility by X-ray but at same time the 
amount of bariumsulphate (100 mg) was low enough to 
enable the hollow microspheres to float. The hollow 
microspheres did not adhere to the gastric mucous and 
floating on the gastric fluid for about more the 12 h. This 
formulation CH2C hollow microsphere loaded with 
barium sulphate at 1st hour. was evident by the X-ray 
photographs taken at 1 h, & 9 h. It is shown in Fig. 5, Fig. 
6, Fig.7 and Fig.8. 
 
Fig 5: Radiographic images (X-ray photographs) of 
rabbit’s stomach to investigate in vivo floating behavior of 
formulation CS2B hollow microspheres loaded with 
barium sulphate at 1st hour. 
 
 
Fig 6: Radiographic images (X-ray photographs) of 
rabbit’s stomach to investigate in vivo floating behavior of 
formulation CS2B hollow microspheres loaded with 
barium sulphate at 9th hour. 
 
 
Fig 7: Radiographic images (X-ray photographs) of 
rabbit’s stomach to investigate in vivo floating behavior of  
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Fig. 8: Radiographic images (X-ray photographs) of 
rabbit’s stomach to investigate in vivo floating behavior of 
formulation CH2C hollow microspheres loaded with 
barium sulphate at 9th hour. 
4.6. In- vitro drug release study: 
Release of Eletriptan Hydrobromide from calcium silicate 
and cholestyramine based microspheres was evaluated in 
pH 2.0 as shown in Table. 4 and Table. 5. Calcium silicate 
based floating drug delivery system provides the 
possibility of enhancing the bioavailability and control the 
release of Eletriptan Hydrobromide exhibiting absorption 
window by prolonging the gastric emptying time of the 
dosage form, ensuring availability of drug at the absorption 
site for the desired period of time. The calcium silicate 
microsphere with adsorbed drug and polymer coating 
showed a drug release ranging from 92.08 ± 3.59 to 98.05 
± 1.99 in Fig.9, when compared to cholestyramine based 
floating microspheres with drug release ranging from 
92.60 ± 3.92 to 98.28 ± 1.60  as in Fig.10.The  release of 
optimized formulations CS2B and CH2C is depicted in 
Fig.11.  From the mathematical modeling of dissolution 
profiles, as shown in Table. 6, CS2B showed higher 
regression co efficient 0.9898 following first order non- 
fickian diffusion kinetic model. 
 
Fig 9: Cumulative percentage drug release in all Calcium silicate based microspheres 
 
 
Fig 10: Cumulative percentage drug release in all Cholestyramine based microspheres. 
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Fig 11: Cumulative percentage drug release in optimized formulations. 
 
Table 4: Percentage drug release of Calcium silicate based Eletriptan Hydrobromide microspheres 
Time 
(Hours) 
CS1A CS1B CS1C CS2A CS2B CS2C 
0 0.00 ± 0.00 0.00 ± 0.00 0.00 ± 0.00 0.00 ± 0.00 0.00 ± 0.00 0.00 ± 0.00 
1 15.96 ± 4.33 13.73 ± 2.17 12.06 ± 0.09 16.19 ± 3.58 10.69 ±1.02 19.47 ± 2.55 
2 20.80 ± 7.51 19.81 ± 2.18 17.25 ± 2.16 25.41 ± 0.77 23.25 ± 1.36 25.08 ± 4.14 
3 27.92 ± 9.49 23.79 ± 4.36 22.47 ± 2.16 30.67 ± 5.87 35.37 ± 1.54 31.97 ± 5.00 
4 33.82±11.35 29.55 ± 4.39 31.22 ± 2.15 36.59 ± 4.57 39.32 ± 1.59 45.77 ± 3.39 
6 38.50±11.41 39.96 ± 6.57 34.14 ± 4.32 45.54 ± 4.56 51.16 ± 1.70 53.39 ± 4.72 
8 49.84 ± 8.01 48.68 ± 4.45 41.83 ± 6.78 49.91 ± 5.93 64.82 ± 1.81 61.31 ± 3.19 
10 63.24 ± 8.04 62.07 ± 5.75 57.68 ± 8.34 57.31 ± 2.24 73.67 ± 1.86 68.77 ± 4.20 
12 82.58 ± 2.20 70.28 ± 5.78 73.12 ± 4.22 62.25 ± 0.09 84.34 ± 1.92 79.77 ± 6.26 
24 95.28 ± 6.02 96.91 ± 2.12 95.40 ± 4.65 95.34 ± 7.51 98.05 ± 1.99 92.08 ± 3.59 
 
 
Table 5: Percentage drug release of Cholestyramine based Eletriptan Hydrobromide microspheres 
 
Time 
(Hours) 
CH1A CH1B CH1C CH2A CH2B CH2C 
0 0.00 ± 0.00 0.00 ± 0.00 0.00 ± 0.00 0.00 ± 0.00 0.00 ± 0.00 0.00 ± 0.00 
1 15.49 ± 8.73 11.19 ± 2.18 25.81 ± 5.34 23.31 ± 4.17 19.24 ± 5.48 19.75 ± 5.71 
2 19.20 ± 6.40 15.50 ± 0.03 29.58 ± 4.65 24.31 ± 4.29 22.47 ± 4.03 27.11 ± 5.13 
3 21.93 ± 5.79 19.84 ± 2.17 33.99 ± 7.48 30.95 ± 9.85 27.59 ± 5.88 33.38±10.13 
4 25.43 ± 7.12 23.82 ± 4.34 40.30±11.04 37.87±11.59 34.74 ± 1.80 44.44 ± 3.71 
6 33.69 ± 6.94 32.20 ± 4.37 44.65±11.72 44.07±11.81 41.31 ± 1.95 57.43 ± 9.06 
8 39.37 ± 8.06 39.01 ± 7.42 49.39±12.66 47.44±11.93 50.41 ± 3.23 65.87 ± 9.81 
10 58.46 ± 2.31 47.47 ± 2.27 84.91 ± 0.80 79.45 ± 3.20 79.93 ± 6.31 78.98 ± 5.40 
12 69.41 ± 5.15 60.73 ± 0.12 91.37 ± 1.13 85.63 ± 1.81 86.62 ± 5.91 90.41 ± 2.92 
24 93.16± 2.49 93.43 ± 2.96 94.74 ± 1.53 92.60 ± 3.92 94.84 ± 0.95 98.28 ± 1.60 
 
 
 
 
 
Shravan et al                                   Journal of Drug Delivery & Therapeutics; 2013, 3(3), 104-112   111 
© 2011, JDDT. All Rights Reserved                                                        ISSN: 2250-1177                                                     CODEN (USA): JDDTAO 
 
Table 6: Regression coefficient (R2) values of Eletriptan Hydrobromide floating microspheres for different kinetic 
models 
Formulation 
Zero-order First-order Higuchi Korsmeyer-Peppas 
R
2
 n 
CS1A 0.7697 0.963 0.9645 0.7262 0.2937 
CS1B 0.7435 0.9513 0.9492 0.0016 0.0518 
CS1C 0.7508 0.9525 0.9336 0.7121 0.3271 
CS2A 0.8963 0.9676 0.9617 0.5794 0.5043 
CS2B 0.9415 0.9506 0.9786 0.5985 0.4657 
CS2C 0.9381 0.9589 0.9641 0.637 0.5819 
CS3A 0.918 0.948 0.9961 0.65 0.5477 
CS3B 0.8426 0.9898 0.9671 0.6927 0.628 
CSC 0.8589 0.9858 0.9706 0.6829 0.523 
CH1A 0.8853 0.9668 0.9859 0.6721 0.3118 
CH1B 0.9593 0.8651 0.9916 0.6877 0.522 
CH1C 0.8414 0.6018 0.7873 0.4446 0.3557 
CH2A 0.9444 0.9629 0.9509 0.5421 0.4125 
CH2B 0.9793 0.9389 0.962 0.591 0.5242 
CH2C 0.8016 0.8804 0.639 0.5982 0.3578 
CH3A 0.8285 0.9195 0.921 0.5708 0.3507 
CH3B 0.8447 0.9446 0.9202 0.6349 0.4684 
CH3C 0.8187 0.9847 0.9592 0.6772 0.4734 
 
Table 7: Stability study for drug content of prepared CS2B and CH2C microspheres 
Sampling (days) Drug content (%) CS2B Drug content (%) CH2C Stability condition 
0 75.29 ± 1.93 56.91±4.49  
 
40 ºC/75% RH 
7 75.25±1.24 56.75±3.98 
15 75.21±1.87 56.63±1.55 
30 75.18±1.85 56.56±1.98 
60 75.16±1.72 56.35±2.11 
90 75.11±1.22 56.14±1.65 
 
4.7. Accelerated Stability studies: 
The objective of stability studies is to predict the shelf life 
of a product by accelerating the rate of decomposition, 
preferably by increasing the temperature and RH. The 
RSM containing selected formulation CS2B and CH2C 
was subjected to stability studies carried out by storing at 
40ºC/75% RH for 3 months (climatic zone IV condition 
for accelerated testing) to assess their stability . These 
samples were analyzed and checked for changes in 
physical appearance and drug content at regular intervals. 
The obtained data is presented in Table 7. From the table, 
it is clear that the formulation did not undergo any 
chemical changes/interaction during the study period. 
5. CONCLUSION: 
The present formulation study of Eletriptan Hydrobromide 
was performed in an attempt to prepare floating drug 
delivery system consisting of floating multiple unit system. 
Incorporation of Calcium silicate in the microspheres 
proved to be an effective method to achieve the desired 
release behavior and buoyancy than incorporation of 
cholestyramine. The performance of these formulations 
was evaluated and the effect of various formulation 
variables was studied. The designed system, combining 
excellent buoyant ability and suitable drug release pattern, 
could possibly be advantageous in terms of increased 
bioavailability of Eletriptan Hydrobromide. Major 
advantages of the system include: (i) ease of preparation, 
(ii) good buoyancy, (iii) high encapsulation efficiency, and 
(iv) sustained drug release over several hours. 
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